Osteonecrosis of the jaws induced by drugs other than bisphosphonates - A call to update terminology in light of new data

Oral Oncology

Volumn 46, Issue 1, 2010, Pages

  Yarom, Noam ^a,b   Elad, Sharon ^c   Madrid, Carlos ^d   Migliorati, Cesar A ^e  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d Department of Ambulatory Care and Community Medicine   (Switzerland)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ZOLEDRONIC ACID;

ANTIANGIOGENIC ACTIVITY; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RELAPSE; CLINICAL FEATURE; DRUG INDUCED OSTEONECROSIS OF THE JAW; DRUG SAFETY; HUMAN; JAW OSTEONECROSIS; LETTER; MULTIPLE MYELOMA; NOMENCLATURE; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; MALE; MANDIBULAR DISEASES; OSTEONECROSIS; TERMINOLOGY AS TOPIC;

EID: 72149119753     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2009.10.004     Document Type: Letter

References (4)

1. Marx R.E., Sawatari Y., and Fortin M. Broumand V Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1567-1575
2. Greuter S., Schmid F., Ruhstaller T., and Thuerlimann B. Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol 19 (2008) 2091-2092
3. Aragon-Ching J.B., Ning Y.M., Chen C.C., Latham L., Guadagnini J.P., Gulley J.L., et al. Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 27 (2009) 221-226
4. Stopeck A, Body JJ, Fujiwara Y, Lipton A, Steger GG, Viniegra M, et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. Europe J Cancer Suppl 2009;7:2 [abstract 2LBA].